International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study

Philip R. Fox; Bruce W. Keene; Kenneth Lamb; Karsten A. Schober; Valerie Chetboul; Virginia Luis Fuentes; Gerhard Wess; Jessie Rose Payne; Daniel F. Hogan; Alison Motsinger-Reif; Jens Häggström; Emilie Trehiou-Sechi; Deborah M. Fine-Ferreira; Reid K. Nakamura; Pamela M. Lee; Manreet K. Singh; Wendy A. Ware; Jonathan A. Abbott; Geoffrey Culshaw; Sabine Riesen; Michele Borgarelli; Michael B. Lesser; Nicole Van Israël; Etienne Côté; John E. Rush; Barret Bulmer; Roberto A. Santilli; Andrea C. Vollmar; Maribeth J. Bossbaly; Nadine Quick; Claudio Bussadori; Janice M. Bright; Amara H. Estrada; Dan G. Ohad; Maria Josefa Fernández-Del Palacio; Jenifer Lunney Brayley; Denise S. Schwartz; Christina M. Bové; Sonya G. Gordon; Seung Woo Jung; Paola Brambilla; N. Sydney Moïse; Christopher D. Stauthammer; Rebecca L. Stepien; Cecilia Quintavalla; Christophe Amberger; Ferenc Manczur; Yong Wei Hung; Remo Lobetti; Marie De Swarte; Alice Tamborini; Carmel T. Mooney; Mark A. Oyama; Andrey Komolov; Yoko Fujii; Romain Pariaut; Masami Uechi; Victoria Yukie Tachika Ohara

doi:10.1111/jvim.15122

International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study

Philip R. Fox, Bruce W. Keene, Kenneth Lamb, Karsten A. Schober, Valerie Chetboul, Virginia Luis Fuentes, Gerhard Wess, Jessie Rose Payne, Daniel F. Hogan, Alison Motsinger-Reif, Jens Häggström, Emilie Trehiou-Sechi, Deborah M. Fine-Ferreira, Reid K. Nakamura, Pamela M. Lee, Manreet K. Singh, Wendy A. Ware, Jonathan A. Abbott, Geoffrey Culshaw, Sabine RiesenMichele Borgarelli, Michael B. Lesser, Nicole Van Israël, Etienne Côté, John E. Rush, Barret Bulmer, Roberto A. Santilli, Andrea C. Vollmar, Maribeth J. Bossbaly, Nadine Quick, Claudio Bussadori, Janice M. Bright, Amara H. Estrada, Dan G. Ohad, Maria Josefa Fernández-Del Palacio, Jenifer Lunney Brayley, Denise S. Schwartz, Christina M. Bové, Sonya G. Gordon, Seung Woo Jung, Paola Brambilla, N. Sydney Moïse, Christopher D. Stauthammer, Rebecca L. Stepien, Cecilia Quintavalla, Christophe Amberger, Ferenc Manczur, Yong Wei Hung, Remo Lobetti, Marie De Swarte, Alice Tamborini, Carmel T. Mooney, Mark A. Oyama, Andrey Komolov, Yoko Fujii, Romain Pariaut, Masami Uechi, Victoria Yukie Tachika Ohara

Veterinary Clinical Sciences

Research output: Contribution to journal › Article › peer-review

90 Scopus citations

Abstract

Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. Hypothesis/Objectives: Observational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH). Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death. Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean ± standard deviation, 1.3 ± 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. Conclusions and Clinical Importance: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.

Original language	English (US)
Pages (from-to)	930-943
Number of pages	14
Journal	Journal of veterinary internal medicine
Volume	32
Issue number	3
DOIs	https://doi.org/10.1111/jvim.15122
State	Published - May 1 2018

Bibliographical note

Publisher Copyright:
Copyright © 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

Keywords

arterial thromboembolism
asymptomatic
congestive heart failure
epidemiology
incidence
outcome
survival

Access

10.1111/jvim.15122

OpenUrl availability

Full text

Cite this

Fox, P. R., Keene, B. W., Lamb, K., Schober, K. A., Chetboul, V., Luis Fuentes, V., Wess, G., Payne, J. R., Hogan, D. F., Motsinger-Reif, A., Häggström, J., Trehiou-Sechi, E., Fine-Ferreira, D. M., Nakamura, R. K., Lee, P. M., Singh, M. K., Ware, W. A., Abbott, J. A., Culshaw, G., ... Tachika Ohara, V. Y. (2018). International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study. Journal of veterinary internal medicine, 32(3), 930-943. https://doi.org/10.1111/jvim.15122

International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study. / Fox, Philip R.; Keene, Bruce W.; Lamb, Kenneth et al.
In: Journal of veterinary internal medicine, Vol. 32, No. 3, 01.05.2018, p. 930-943.

Research output: Contribution to journal › Article › peer-review

Fox, PR, Keene, BW, Lamb, K, Schober, KA, Chetboul, V, Luis Fuentes, V, Wess, G, Payne, JR, Hogan, DF, Motsinger-Reif, A, Häggström, J, Trehiou-Sechi, E, Fine-Ferreira, DM, Nakamura, RK, Lee, PM, Singh, MK, Ware, WA, Abbott, JA, Culshaw, G, Riesen, S, Borgarelli, M, Lesser, MB, Van Israël, N, Côté, E, Rush, JE, Bulmer, B, Santilli, RA, Vollmar, AC, Bossbaly, MJ, Quick, N, Bussadori, C, Bright, JM, Estrada, AH, Ohad, DG, Fernández-Del Palacio, MJ, Lunney Brayley, J, Schwartz, DS, Bové, CM, Gordon, SG, Jung, SW, Brambilla, P, Moïse, NS, Stauthammer, CD, Stepien, RL, Quintavalla, C, Amberger, C, Manczur, F, Hung, YW, Lobetti, R, De Swarte, M, Tamborini, A, Mooney, CT, Oyama, MA, Komolov, A, Fujii, Y, Pariaut, R, Uechi, M & Tachika Ohara, VY 2018, 'International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study', Journal of veterinary internal medicine, vol. 32, no. 3, pp. 930-943. https://doi.org/10.1111/jvim.15122

@article{7744f56a1a214984981cfc6c2ecc11f0,

title = "International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study",

abstract = "Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. Hypothesis/Objectives: Observational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH). Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death. Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean ± standard deviation, 1.3 ± 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. Conclusions and Clinical Importance: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.",

keywords = "arterial thromboembolism, asymptomatic, congestive heart failure, epidemiology, incidence, outcome, survival",

author = "Fox, {Philip R.} and Keene, {Bruce W.} and Kenneth Lamb and Schober, {Karsten A.} and Valerie Chetboul and {Luis Fuentes}, Virginia and Gerhard Wess and Payne, {Jessie Rose} and Hogan, {Daniel F.} and Alison Motsinger-Reif and Jens H{\"a}ggstr{\"o}m and Emilie Trehiou-Sechi and Fine-Ferreira, {Deborah M.} and Nakamura, {Reid K.} and Lee, {Pamela M.} and Singh, {Manreet K.} and Ware, {Wendy A.} and Abbott, {Jonathan A.} and Geoffrey Culshaw and Sabine Riesen and Michele Borgarelli and Lesser, {Michael B.} and {Van Isra{\"e}l}, Nicole and Etienne C{\^o}t{\'e} and Rush, {John E.} and Barret Bulmer and Santilli, {Roberto A.} and Vollmar, {Andrea C.} and Bossbaly, {Maribeth J.} and Nadine Quick and Claudio Bussadori and Bright, {Janice M.} and Estrada, {Amara H.} and Ohad, {Dan G.} and {Fern{\'a}ndez-Del Palacio}, {Maria Josefa} and {Lunney Brayley}, Jenifer and Schwartz, {Denise S.} and Bov{\'e}, {Christina M.} and Gordon, {Sonya G.} and Jung, {Seung Woo} and Paola Brambilla and Mo{\"i}se, {N. Sydney} and Stauthammer, {Christopher D.} and Stepien, {Rebecca L.} and Cecilia Quintavalla and Christophe Amberger and Ferenc Manczur and Hung, {Yong Wei} and Remo Lobetti and {De Swarte}, Marie and Alice Tamborini and Mooney, {Carmel T.} and Oyama, {Mark A.} and Andrey Komolov and Yoko Fujii and Romain Pariaut and Masami Uechi and {Tachika Ohara}, {Victoria Yukie}",

note = "Publisher Copyright: Copyright {\textcopyright} 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.",

year = "2018",

month = may,

day = "1",

doi = "10.1111/jvim.15122",

language = "English (US)",

volume = "32",

pages = "930--943",

journal = "Journal of veterinary internal medicine",

issn = "0891-6640",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats

T2 - The REVEAL Study

AU - Fox, Philip R.

AU - Keene, Bruce W.

AU - Lamb, Kenneth

AU - Schober, Karsten A.

AU - Chetboul, Valerie

AU - Luis Fuentes, Virginia

AU - Wess, Gerhard

AU - Payne, Jessie Rose

AU - Hogan, Daniel F.

AU - Motsinger-Reif, Alison

AU - Häggström, Jens

AU - Trehiou-Sechi, Emilie

AU - Fine-Ferreira, Deborah M.

AU - Nakamura, Reid K.

AU - Lee, Pamela M.

AU - Singh, Manreet K.

AU - Ware, Wendy A.

AU - Abbott, Jonathan A.

AU - Culshaw, Geoffrey

AU - Riesen, Sabine

AU - Borgarelli, Michele

AU - Lesser, Michael B.

AU - Van Israël, Nicole

AU - Côté, Etienne

AU - Rush, John E.

AU - Bulmer, Barret

AU - Santilli, Roberto A.

AU - Vollmar, Andrea C.

AU - Bossbaly, Maribeth J.

AU - Quick, Nadine

AU - Bussadori, Claudio

AU - Bright, Janice M.

AU - Estrada, Amara H.

AU - Ohad, Dan G.

AU - Fernández-Del Palacio, Maria Josefa

AU - Lunney Brayley, Jenifer

AU - Schwartz, Denise S.

AU - Bové, Christina M.

AU - Gordon, Sonya G.

AU - Jung, Seung Woo

AU - Brambilla, Paola

AU - Moïse, N. Sydney

AU - Stauthammer, Christopher D.

AU - Stepien, Rebecca L.

AU - Quintavalla, Cecilia

AU - Amberger, Christophe

AU - Manczur, Ferenc

AU - Hung, Yong Wei

AU - Lobetti, Remo

AU - De Swarte, Marie

AU - Tamborini, Alice

AU - Mooney, Carmel T.

AU - Oyama, Mark A.

AU - Komolov, Andrey

AU - Fujii, Yoko

AU - Pariaut, Romain

AU - Uechi, Masami

AU - Tachika Ohara, Victoria Yukie

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. Hypothesis/Objectives: Observational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH). Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death. Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean ± standard deviation, 1.3 ± 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. Conclusions and Clinical Importance: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.

AB - Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. Hypothesis/Objectives: Observational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH). Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death. Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean ± standard deviation, 1.3 ± 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. Conclusions and Clinical Importance: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.

KW - arterial thromboembolism

KW - asymptomatic

KW - congestive heart failure

KW - epidemiology

KW - incidence

KW - outcome

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85045749976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045749976&partnerID=8YFLogxK

U2 - 10.1111/jvim.15122

DO - 10.1111/jvim.15122

M3 - Article

C2 - 29660848

AN - SCOPUS:85045749976

SN - 0891-6640

VL - 32

SP - 930

EP - 943

JO - Journal of veterinary internal medicine

JF - Journal of veterinary internal medicine

IS - 3

ER -

International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this